Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 7, p. 655, doi. 10.1002/cpdd.979
- Publication type:
- Article
Works matching IS 2160763X AND DT 2023 AND VI 12 AND IP 7
Results: 12
1
2
Anti‐Monkeypox Infection Approaches: From Prevention to Therapeutic Lines.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 7, p. 659, doi. 10.1002/cpdd.1275
- By:
- Publication type:
- Article
3
Pharmacokinetics, Bioequivalence, and Safety of Esomeprazole Magnesium Enteric‐Coated Capsules in Healthy Chinese Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 7, p. 691, doi. 10.1002/cpdd.1273
- By:
- Publication type:
- Article
4
The Pharmacokinetics and Bioequivalence of Desvenlafaxine Succinate in Chinese Healthy Subjects Under Fasting and Fed States.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 7, p. 699, doi. 10.1002/cpdd.1272
- By:
- Publication type:
- Article
5
Evaluation of Drug–Drug Interaction Potential of Enarodustat (JTZ‐951) Using a Cytochrome P450 Probe Cocktail.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 7, p. 667, doi. 10.1002/cpdd.1263
- By:
- Publication type:
- Article
6
Comparison of Two Manufacturing Processes of Daprodustat for Bioequivalence and Dissolution in Healthy Volunteers: A Randomized Crossover Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 7, p. 739, doi. 10.1002/cpdd.1257
- By:
- Publication type:
- Article
7
Pharmacokinetics of Enarodustat in Non‐Japanese and Japanese Healthy Subjects and in Patients With End‐Stage Renal Disease on Hemodialysis.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 7, p. 683, doi. 10.1002/cpdd.1252
- By:
- Publication type:
- Article
8
Bioequivalence Study of Ezetimibe Tablets After a Single Oral Dose of 10 mg in Healthy Japanese Subjects Under Fasting Conditions.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 7, p. 731, doi. 10.1002/cpdd.1245
- By:
- Publication type:
- Article
9
First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose, Food‐Effect, and Absolute Bioavailability Trials to Assess the Pharmacokinetics, Safety, and Tolerability of Pritelivir, a Nonnucleoside Helicase‐Primase Inhibitor Against Herpes Simplex Virus in Healthy Subjects
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 7, p. 749, doi. 10.1002/cpdd.1241
- By:
- Publication type:
- Article
10
Pharmacokinetics of AXA1665, a Novel Composition of Amino Acids, in Comparison With Protein Supplement: A Single‐Dose, Open‐Label, Randomized Study in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 7, p. 718, doi. 10.1002/cpdd.1227
- By:
- Publication type:
- Article
11
A Bioequivalence Study With Pharmacokinetic Endpoints for Azithromycin Eye Drops.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 7, p. 761, doi. 10.1002/cpdd.1226
- By:
- Publication type:
- Article
12
Phase 1 Clinical Results for NP10679, a pH‐sensitive GluN2B‐selective N‐methyl‐d‐aspartate Receptor Inhibitor.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 7, p. 706, doi. 10.1002/cpdd.1217
- By:
- Publication type:
- Article